Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis

Next Previous
Search
Trial Profile

VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms VOYAGE
  • Sponsors Viking Therapeutics

    • Most Recent Events

    • 19 Nov 2024 Results presented in the Viking Therapeutics Media Release.
    • 19 Nov 2024 According to a Viking Therapeutics media release, final results from the company's Phase 2b clinical trial of VK2809 were published at the 75th Liver Meeting 2024 and the annual meeting of the American Association for the Study of Liver Disease (AASLD).
    • 12 Nov 2024 According to a Viking Therapeutics Media Release, data from this study will be presented on Tuesday, November 19, 2024, 11:00 - 11:10 a.m. Pacific Time, in an oral late breaker presentation (Late Breaking Abstract Parallel Session 3) at the 75th Liver Meeting 2024, the annual meeting of the American Association for the Study of Liver Disease (AASLD), being held November 15-19, 2024, in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top